Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers.

Molecular cancer therapeutics - 1 Oct 2017

Cho Sung-Yup, Han Jee Yun, Na Deukchae, Kang Wonyoung, Lee Ahra, Kim Jooyoung, Lee Jieun, Min Seoyeon, Kang Jinjoo, Chae Jeesoo, Kim Jong-Il, Park Hansoo, Lee Won-Suk, Lee Charles

Abstract excerpt

Colorectal cancer is the third most commonly diagnosed cancer in the world, and exhibits heterogeneous characteristics in terms of genomic alterations, expression signature, and drug responsiveness. Although there have been considerable efforts to classify this disease based on high-throughput sequencing techniques, targeted treatments for specific subgroups have been limited. KRAS and BRAF mutations are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aniline Compounds
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to bcl-X Protein

Share to Imidazoles

Share to Myeloid Cell Leukemia Sequence 1 Protein

Share to Naphthoquinones

Share to Sulfonamides

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 28611106
DOI: 10.1158/1535-7163.MCT-16-0735

Genes

BRAF
KRAS
MCL1
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers.PMID 28611106Read ↗

Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancerSemantic proximity Read ↗

mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.Semantic proximity Read ↗

Bcl-xL is a key mediator of apoptosis following KRAS <sup>G12C</sup> inhibition in <i>KRAS</i> <sup> <i>G12C</i> </sup> mutant colorectal cancerSemantic proximity Read ↗

CRISPR screens identify a novel combination treatment targeting BCL-XL and WNT signaling for KRAS/BRAF-mutated colorectal cancers.Semantic proximity Read ↗

Bcl-xL is an oncogenic driver in colorectal cancer.Semantic proximity Read ↗

Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors.Semantic proximity Read ↗

Anti-cancer drug discovery and developmentSemantic proximity Read ↗

Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.Semantic proximity Read ↗

Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitorsSemantic proximity Read ↗

MCL1 nuclear translocation induces chemoresistance in colorectal carcinomaSemantic proximity Read ↗

BCL-2 Family Inhibition Enhances mTORC1/2 Inhibition in PIK3CA-Mutant Colorectal Cancer.Semantic proximity Read ↗

Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-XL inhibitor ABT-263 in KRAS-mutant colorectal cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.